Pre-made Ongericimab benchmark antibody ( Whole mAb, anti-PCSK9 therapeutic antibody, Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ongericimab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ongericimab (formerly JS 002) is a recombinant humanised anti-PCSK9 monoclonal antibody, for subcutaneous injection, being developed by Shanghai Junshi.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-403-1mg	1mg	3090
GMP-Bios-ab-403-10mg	10mg	Inquiry
GMP-Bios-ab-403-100mg	100mg	Inquiry
GMP-Bios-ab-403-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ongericimab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody
INN Name	Ongericimab
Target	PCSK9
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Shanghai Junshi Biosciences
Conditions Approved	na
Conditions Active	Hypercholesterolemia
Conditions Discontinued	na
Development Tech	na